自体树突细胞联合细胞因子诱导的杀伤细胞治疗晚期非小细胞肺癌的临床研究

发布时间：2018-04-20 09:59

本文选题：树突状细胞 + 细胞因子诱导杀伤细胞　；参考：《解放军医学杂志》2017年09期

【摘要】：目的评价自体树突细胞(DC)联合细胞因子诱导的杀伤细胞(CIK)治疗晚期非小细胞肺癌的临床疗效和安全性。方法采集39例晚期非小细胞肺癌患者的外周血单个核细胞(PBMC),经实验室体外培养诱导产生DC和CIK细胞,经流式细胞术进行表型鉴定后回输给患者。于第7、9、11、13天皮下注射DC,第11、13天静脉回输CIK。比较39例患者治疗前后的临床疗效、免疫功能并评价安全性。结果 39例患者中,完全缓解(CR)2例,部分缓解(PR)10例,稳定(SD)15例,进展(PD)12例;39例患者经DC-CIK治疗后的客观反应率为30.7%,疾病控制率为69.2%。接受≥2个疗程免疫治疗的患者生存率明显高于接受1个疗程的患者。与治疗前比较,治疗后患者外周血CD3~+CD4~+CD8 、CD3~+CD4 CD8~+、CD3~+CD19 、CD3 CD19~+、CD3 CD16~+CD56~+、CD3~+CD16~+CD56~+、CD3~+HLA-DR 、CD3~+HLA-DR~+、CD3~+CD28~+CD8~+细胞亚群的比例无明显变化(P0.05),Th1细胞、Th2细胞比例明显升高,CD3~+CD4~+CD25~+T细胞(即调节性T细胞,Treg细胞)比例明显降低,差异均有统计学意义(P0.05)。治疗过程中,39例患者均未出现明显不良反应。结论 DC-CIK细胞免疫治疗为晚期非小细胞肺癌提供了一种新的安全有效的治疗选择,可有效改善患者的免疫抑制状态,提高抗肿瘤免疫反应,降低肿瘤复发和转移的可能性。
[Abstract]:Objective to evaluate the efficacy and safety of autologous dendritic cell carcinoma (DC) combined with cytokine induced killer cell line CIK in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Peripheral blood mononuclear cells (PBMC) were collected from 39 patients with advanced non-small cell lung cancer (NSCLC). DC and CIK cells were induced by laboratory culture in vitro. DC3 was injected subcutaneously on day 7 and CIK was injected intravenously on day 1113. To compare the clinical efficacy, immune function and safety of 39 patients before and after treatment. Results among the 39 patients, 2 cases had complete remission, 10 cases had partial remission, 15 cases had stable SDN. The objective response rate and disease control rate were 30.7 and 69.2 after DC-CIK treatment. The survival rate of patients receiving more than 2 courses of immunotherapy was significantly higher than that of patients receiving one course of treatment. Compared with pre-treatment, The percentage of cells decreased significantly. The difference was statistically significant (P 0.05). There were no obvious adverse reactions in 39 patients. Conclusion DC-CIK cell immunotherapy provides a new safe and effective treatment option for advanced non-small cell lung cancer. It can effectively improve the immunosuppressive state of patients, increase the anti-tumor immune response, and reduce the possibility of tumor recurrence and metastasis.
【作者单位】：军事医学科学院附属医院造血干细胞移植科;
【基金】：国家科技重大专项“十二五”计划基金资助项目(2009ZX09503)~~
【分类号】：R734.2

【相似文献】